Blood
Articles in this Issue
Clonal architecture and growth dynamics of ibrutinib-resistant CLL: Oligoclonal BTK/PLCG2 mutations and emerging non-BTK/PLCG2 drivers
Abstract In patients with chronic lymphocytic leukemia (CLL) undergoing treatment with ibrutinib, progressive disease (PD) frequently manife...
Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia
Abstract Background: Acute leukemia is the most common hematological malignancy, mainly including acute myeloid leukemia (AML) and acute lym...
Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need
Abstract Introduction BsAb are an emerging off-the-shelf immunotherapy for R/R LBCL. Epcoritamab and glofitamab have received accelerated FD...
Metabolic tumor volume is an independent predictor of worse survival in 57 elderly patients with DLBCL
Abstract INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is no longer considered a unique entity. In addition to molecular features, met...
Trends in AML vs MDS mortality in the United States older adults from 1999-2023-a CDC wonder database analysis
Abstract Introduction: Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) both primarily blood cancers of...
A prospective Study of whole genome sequencing for genomic profiling and risk determination in MDS
Abstract Introduction: Genetic risk stratification in MDS is critical to predict disease outcomes and to direct therapy. Our group has devel...
Pharmacogenetic variants in UGT1A1/UGT1A3 and ABCC2 associate with deferasirox efficacy in transfusion-dependent thalassemia.
Abstract Background: Patients with transfusion-dependent thalassemia (TDT) require blood transfusions generally every 2-5 weeks, depending o...
Real-world evaluation of cardiac outcomes after CAR-T in patients with hematologic malignancies
Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of relapsed or refractory hematologic ma...
Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: Results from a randomized, multicenter, placebo-controlled phase 3 trial
Abstract Introduction: Hetrombopag is a novel oral thrombopoietin receptor agonist (TPO-RA) approved in China for adults with chronic immune...
Phase 3 Study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3 Study design
Abstract Warm autoimmune hemolytic anemia (wAIHA) is the most common subtype of AIHA, accounting for ~60-70% of cases. It results from immun...
Peri-transplant ruxolitinib therapy significantly improves GVHD-free, relapse-free survival rates in transplantation for myelofibrosis
Abstract Introduction Myelofibrosis (MF) is an advanced haematological malignancy manifested by the presence of splenomegaly, B-symptoms and...
Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors
Abstract Background: Menin inhibitors have demonstrated promising clinical efficacy in multiple subtypes of acute leukemia, with revumenib b...
Demographic, neurocognitive, disease impact, and social characteristics of patients served by embedded neuropsychological services in an adult sickle cell clinic
Abstract Individuals with sickle cell disease (SCD) face elevated risk of neurocognitive and psychosocial difficulties due to medical factor...
Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma
Abstract Introduction Ciltacabtagene autoleucel (cilta-cel) has demonstrated unprecedented response rates and progression-free survival (PFS...
Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms
Abstract Introduction: Myeloproliferative neoplasms (MPNs), which include essential thrombocythemia (ET), polycythemia vera (PV), and myelof...
An integrative prognostic model for transplant outcomes in myelofibrosis
Abstract Introduction Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative option for patients...
Fibroblast-activating protein as a biomarker for blood-induced joint inflammation in hemophilia
Abstract Introduction: Bleeding in patients with hemophilia A or B typically affects large joints such as elbows, knees and ankles. Bleeding...
Analysis of immune parameters and effect of immunoglobulin replacement therapy on infection, survival and non-relapse mortality following CD19 CAR T-cell therapy
Abstract The relationship between baseline immune status and immune reconstitution post CD19 CAR T-cell therapy with risk of infection, non-...
Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AML
Abstract Introduction: HLA allelic diversity allows for the presentation of broad peptide repertoires to alloreactive donor T-cells and can...
Risk of bleeding in 15,495 patients with myeloproliferative neoplasms by treatment type and thrombotic history
Abstract Patients with myeloproliferative neoplasms (MPNs) are inherently at increased risk of both thrombotic and bleeding events due to th...
Contemporary survival trends in patients with adult T-cell leukemia/lymphoma (ATLL) in the United States: Insights from the national cancer database
Abstract Introduction: Adult T-cell leukemia/lymphoma (ATLL) is a rare blood disorder associated with human T-cell leukemia virus type 1 (HT...
Initiating Eltrombopag (EPAG) Early for aplastic Anemia (AA) may Lead to greater clinical benefits: A systematic review and meta-analysis
Abstract Background Aplastic anemia (AA) is a bone marrow failure syndrome. Whether the combination of TPO-RAs and IST is superior to IST alo...
HOPE (Hematology/Oncology Practical Education)
Abstract Introduction Patients with hematologic malignancies are living longer than ever before, thanks, in part, due to...
Immune Dysregulation and State-Transition Transcriptomic Signatures Underlying Pediatric Chronic Myeloid Leukemia Pathogenesis
Abstract Chronic myeloid leukemia (CML) accounts for approximately 2% of all leukemias in children under 15 and 9% in adolescents aged 15 to...
Lack of efficacy of levocarnitine for the treatment of pegylated asparaginase-related hepatotoxicity during induction or salvage chemotherapy in adults with acute lymphoblastic leukemia: A comparative, retrospective, University of California hematologic malignancies consortium (UCHMC) study
Abstract Background: Pegylated E. coli L-asparaginase (PEGAsp) is a common component of therapy for acute lymphoblastic leukemia (ALL). Hepa...